Skip to content

Clinical Observation of Gelan Xiaoke Pill in the Treatment of Abnormal Glucose Tolerance and Diabetic Patients

Clinical Observation of Gelan Xiaoke Pill in the Treatment of Abnormal Glucose Tolerance and Diabetic Patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300070344
Enrollment
Unknown
Registered
2023-04-10
Start date
2023-04-10
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

experimental group:Basic Western Medicine Treatment + Taking Gelan Xiaoke Pill for 12 weeks
experimental group:Taking Gelan Xiaoke Pill for 12 weeks

Sponsors

Southwest Medical University Affiliated Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. meet the diagnostic criteria of Western medicine and TCM syndrome differentiation criteria ; 2. 30-80 years old ; 3. Voluntary clinical observation and informed consent.

Exclusion criteria

Exclusion criteria: 1. secondary DM patients ; 2. patients with severe primary diseases of heart, brain, liver, lung, kidney and other important organ systems ; 3. those who are known to be allergic or allergic to the drug components of this study ; 4. patients with mental illness can not cooperate with clinical treatment and observation ; 5. Patients with acute metabolic disorders such as DM ketoacidosis and co-infection in the past 1 month ; 6. Women in pregnancy and lactation.

Design outcomes

Primary

MeasureTime frame
glycosylated hemoglobin;

Secondary

MeasureTime frame
adiponectin;fasting blood glucose;2h postprandial blood glucose;fasting insulin level;insulin resistance index;total cholesterol;triglyceride;low-density lipoprotein cholesterol;high density lipoprotein-cholesterol;superoxide dismutase;malonaldehyde;Reduced glutathione peroxidase;advanced oxidation protein products;immunoglobin A;immunoglobin M;immunoglobin G;complement C3;complement C4;systolic pressure;diastolic pressure;

Countries

China

Contacts

Public ContactSijin Yang

The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University

ysjimn@sina.com+86 13608286028

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026